2024
- ACS-CAN Letter to HHS Office of the Inspector General re: a new regulatory safe harbor to the federal health care program anti-kickback statute (February 2024)
- ACOG Amicus Brief in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine et al. (February 2024)
- One Voice Against Cancer (OVAC) sign-on letter to Congressional Appropriators regarding FY 2024 funding for NIH, NCI, and CDC
2023
- SGO comments on White House Initiative on Women’s Health Research (December 2023)
- SGO letter welcoming NIH Director, Dr. Monica Bertagnolli (December 2023)
- SGO comment letter to FDA on Quality Management Maturity Program for Drug Manufacturing Establishments (December 2023)
- SGO response to Senator Cassidy’s request for information on modernizing the NIH (October 2023)
- Comment Letter to CMS regarding CY 2024 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (September 2023)
- Comment Letter to CMS regarding CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies (September 2023)
- Letter to Congressional Appropriations Leadership regarding FY 2024 Requests (September 2023)
- SGO/GOG Foundation joint comment letter to FDA re: E6(R3) Guideline for Good Clinical Practice; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; Draft Guidance for Industry (September 2023)
- Comment Letter to Energy & Commerce Committee Chair Cathy McMorris Rodgers on Stop Drug Shortages Act discussion draft (August 2023)
- Letter urging Congress to act to address chemotherapy shortages through PAHPA reauthorization (July 2023)
- Response to Drug Shortages RFI released by Energy & Commerce Committee Chair Cathy McMorris Rodgers and Senate Finance Committee Ranking Member Mike Crapo (July 2023)
- Comment Letter to NCI on Strategies to Expand and Enhance Development of the Molecular Cancer Prevention and Cancer Interception Research Workforce (June 2023)
- Letter to FDA Commissioner Califf re: Chemotherapy Shortages (June 2023)
- Comment letter to FDA on Docket No. FDA-2020-D-1057; Notification of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act (June 2023)
- Letter to Co-Sponsors of H.R. 2474, the Strengthening Medicare for Patients and Providers Act (May 17, 2023)
- Letter to House and Senate Defense Appropriations leadership re: SGO’s FY 2024 appropriations requests (May 2023)
- AMA Federation letter to Congress regarding H.R. 2474, the Strengthening Medicare for Patients and Providers Act (April 2023)
- AAMC Ad Hoc Group for Medical Research sign on letter in support of increased FY24 appropriations for the National Institutes of Health (NIH) (March 2023)
- FORCE/NCCN letter to Congress in support if the Reducing Hereditary Cancer Act (March 2023)
- National Roundtable on Cervical Cancer letter to CMS regarding changes to coverage of screening for cervical cancer with HPV testing (March 2023)
- Response to NIH RFI on the research project grant review process (March 2023)
- Comment letter to CMS regarding the proposed rule on prior authorization (March 2023)
- ACOG Amicus Brief in Alliance for Hippocratic Medicine v. FDA (February 2023)
2022
- Defense Health Research Consortium letter to U.S. Department of Defense re: FY2024 funding for the Congressionally Directed Medical Research Program (November 2022)
- SGO response to Congressional RFI on MACRA and Medicare payment system reform (October 2022)
- SGO letter to Congressional leadership re: CY2023 Medicare Physician Fee Schedule cuts (October 2022)
- SGO comment letter to the Centers for Medicare and Medicaid Services (CMS) re: Medicare Physician Fee Schedule proposed rule for calendar year CY2023 (September 2022)
- Telehealth stakeholder letter to U.S. Senate (September 2022)